KCTBASE

비소세포폐암에 사용되는 항암화학요법의 요양급여기준 적절성 평가
Assessment of appropriateness of standard for insurance coverage on chemotherapy used in non-small cell lung cancer (NSCLC)

한국임상약학회지 2011년 21권 2호 p.193 ~ p.207

김정연(Kim Jeong-Yeon) - 숙명여자대학교 약학대학
박은지(Park Eun-Ji) - 숙명여자대학교 약학대학
배민경(Bae Min-kyung) - 부산대학교 약학대학
윤정현(Yoon Jeong-Hyun) - 부산대학교 약학대학

Abstract

Purpose: The purpose of this study is to assess appropriateness of current standard for insurance coverage by Health Insurance Review & Assessment Service (HIRA) on chemotherapy used in the treatment of advanced non-small cell lung cancer (NSCLC), by reviewing a variety of clinical evidences, and thereby, if needed, to propose an updated evidence-based recommendations.

Methods: We collected data from HIRA regarding on the insurance standard which includes the scope and conditions for coverage on systemic chemotherapy of NSCLC. We performed a search for clinical databases and examined the most current clinical evidence from clinical literature including various clinical practice guidelines. Based on the collected data the appropriateness of HIRA standard for insurance coverage of chemotherapy of NSCLC was assessed.

Results: Collected data demonstrated that HIRA standard did not reflect the most current clinical practice and evidence. Some were inappropriately listed in HIRA formulary and accepted as a chemotherapy being covered by insurance, despite the lack of evidences of clinical efficacy or superiority over other chemotherapeutic agents or regimens. In addition, there seems to be a need for a modification on the standard for insurance coverage of certain newer chemotherapeutic agents based on the current accumulated data showing their clinical efficacy and benefits in the selected group of NSCLC patients. Therefore, we concluded that current HIRA standard for insurance coverage on chemotherapy of NSCLC needs to be revised and we proposed an updated recommendation based on these latest clinical evidences.

Conclusion: The standard for insurance coverage of chemotherapy should be continually examined its appropriateness based on the most recent clinical evidences in a timely manner so as to provide the most effective and safe therapy to cancer patients.

키워드

non-small cell lung cancer (NSCLC), Health Insurance Review & Assessment Service (HIRA), chemotherapy, targeted therapy

KMID : 0941820110210020193

원문 및 링크아웃 정보

등재저널 정보

주제코드

주제명(Target field)

연구대상(Population)

연구참여(Sample size)

대상성별(Gender)

질병특성(Condition Category)

연구환경(Setting)

연구설계(Study Design)

연구기간(Period)

중재방법(Intervention Type)

중재명칭(Intervention Name)

키워드(Keyword)

유효성결과(Recomendation)

lack of evidence: The standard for insurance coverage of chemotherapy should be continually examined its appropriateness based on the most recent clinical evidences

연구비지원(Fund Source)

근거수준평가(Evidence Hierarchy)

출판년도(Year)

참여저자수(Authors)

대표저자

DOI

KCD코드

ICD 03

건강보험코드

비소세포폐암에 사용되는 항암화학요법의 요양급여기준 적절성 평가 Assessment of appropriateness of standard for insurance coverage on chemotherapy used in non-small cell lung cancer (NSCLC)

Abstract

키워드

비소세포폐암에 사용되는 항암화학요법의 요양급여기준 적절성 평가
Assessment of appropriateness of standard for insurance coverage on chemotherapy used in non-small cell lung cancer (NSCLC)